Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ® Assay in Multiple Myeloma
Adaptive Biotechnologies, a leader in combining next-generation sequencing (NGS) and sophisticated bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into a collaboration agreement with Amgen to utilize Adaptive’s NGS-based clonoSEQ Assay in the Phase 3 CANDOR study, sponsored by Amgen in collaboration with Janssen, comparing Kyprolis® (carfilzomib), Darzalex® (daratumumab), and dexamethasone with Kyrpolis and dexamethasone. Adaptive’s NGS-based clonoSEQ Assay will be utilized to measure minimal residual disease (MRD) status in patients with relapsed or refractory Multiple Myeloma (MM).
“Incorporating MRD measurement by the clonoSEQ Assay offers Amgen the ability to accurately assess the depth of response generated by Kyprolis treatment in patients with relapsed or refractory MM,” said Chad Robins, President, CEO and Co-Founder of Adaptive Biotechnologies. “This is the second collaboration with Amgen to assess MRD in oncology clinical studies, and we are thrilled to continue to expand our work with such an industry-leading partner.”
Announced in January, the first collaboration with Amgen assesses MRD in patients with Acute Lymphoblastic Leukemia (ALL). Through this second collaboration, the companies will work towards further demonstrating the clinical utility of MRD detection in patients with relapsed or refractory MM treated with Kyprolis.
About Minimal/Measurable Residual Disease
Minimal/measurable residual disease (MRD) in hematologic malignancies refers to cancer cells that remain in the body of a person with cancer after treatment. These cells can be present at levels undetectable by traditional morphologic, microscopic examination of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as next-generation sequencing utilized by the Adaptive Biotechnologies clonoSEQ Assay, are needed for reliable detection of MRD at levels below the limits of traditional assessment.
About the clonoSEQ ® Assay
The Adaptive Biotechnologies clonoSEQ Assay enables physicians to utilize a molecular, next-generation sequencing-based minimal/measureable residual disease (MRD) detection method. The clonoSEQ Assay detects and quantifies DNA sequences found in malignant cells which can be tracked throughout treatment. This robust assay provides consistent, accurate measurement of disease burden which potentially allows physicians to visualize response to treatment over time. Adaptive intends to seek 510(K) marketing authorization from FDA for the clonoSEQ Assay.
About Adaptive Biotechnologies ®
Adaptive Biotechnologies is a pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive’s mission is to translate immunosequencing discoveries into clinical diagnostics and therapeutics to improve patient care. For more information, please visit adaptivebiotech.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
New Direct-to-home Satellite TV Bouquet for the Former Yugoslavian Countries from Telekom Srbija and SES15.11.2018 13:34 | Tiedote
Viewers in Serbia, Bosnia and Herzegovina, and Montenegro will soon have access to new content delivered by Telekom Srbija from SES’ key orbital location at 23.5 degrees East. SES announced today that the main telecommunication operator in Serbia has signed a multi-year and multi-transponder contract for service on its Astra satellite to launch Telekom Srbija’s new Direct-to-Home (DTH) platform which will start broadcasting in all three countries simultaneously mid-December. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005405/en/ New Direct-to-home Satellite TV Bouquet for the Former Yugoslavian Countries from Telekom Srbija and SES (Photo: Business Wire) The new DTH platform will enable Telekom Srbija to broadcast more than 150 channels, including up to 30 in High Definition (HD). All Serbian public television channels will also be available on the platform, bringing a complete selection of content to viewers in the
Great Eastern Energy Corporation to Venture into Shale Gas Exploration15.11.2018 13:18 | Tiedote
Great Eastern Energy Corporation Limited (LSE: GEEC), the fully integrated, leading Indian Coal Bed Methane (“CBM”) Company, today announced an upgrade in its resources at its Raniganj (South) block, which has been provided by the independent reserve engineers, Advance Resources International, Inc. (“ARI”). The Government of India has permitted exploration and exploitation of all types of hydrocarbons including shale resources under the existing CBM Contracts. ARI has made the following assessment of the CBM and Shale resources in the Raniganj (South) block: Classification Category SHALE Resources (TCF) CBM Resources (TCF) Total Resources (TCF) Original-Gas-In-Place (“OGIP”) Low Estimate 1.40 2.62 4.02 Best Estimate 3.51 6.13 High Estimate 6.63 9.25 Classification Resource Type Category Gross Recoverable Gas (BCF) Total Future Net Revenues ($ Million) Undiscounted Discounted at 10% per annum Reserves CBM 1P 336.00 $2,037.00 $675.50 2P 510.80 $3,073.00 $965.90 3P 594.70 $3,535.10 $1,076
MultiBank Group Expands Across Europe Making It One of the Largest Financial Derivatives Companies Worldwide15.11.2018 12:46 | Tiedote
In December 2017, MultiBank Group announced the launch of its Asset Management business and the establishment of its European headquarter in Frankfurt, Germany. Since then, the Group’s asset management business has taken off, while the performance of the MultiBank Index linked Note, listed on the Frankfurt Stock Exchange, has reached an all time high at EUR 1,357 today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005376/en/ MultiBank Group Global Presence. (Photo: Business Wire) As such, with the expansion in Europe, the Group has now offices in Hong Kong, Frankfurt, Sydney, Vienna, Barcelona, Beijing, Guangzhou, Ho Chi Minh City, Los Angeles, Cyprus, the British Virgin Islands and the Cayman Islands, with further prompt expansion anticipated in Dubai, London, Santiago (Chile) and Jakarta (Indonesia). This will make MultiBank Group one of the largest online financial derivatives providers with over 310,000 clients a
GSMA Welcomes Germany’s 5G Spectrum Award, but Cautions against Unnecessary Conditions15.11.2018 11:00 | Tiedote
The GSMA today welcomed the German government’s decision to release the entire 3.4 to 3.8 GHz band (C-Band), essential for the future development of 5G services globally. Making available all of the spectrum in this critical band for 5G, in a timely manner, shows Germany’s commitment to European and global 5G leadership. However, the GSMA warns that some of the currently proposed conditions on the allocation of these vital frequencies may slow Germany’s 5G future. Ultra-fast 5G networks will form the foundation of the world’s digital economy, supporting a wide variety of industry sectors. Imposing unnecessary conditions that limit mobile operators’ ability and potential to deliver 5G creates a risk for all, industries and citizens alike. “The C-Band is the most vital frequency band for 5G. Germany is demonstrating 5G leadership in the timely release of this vital spectrum, but risks undercutting its 5G future with unnecessary obligations,” said Mats Granryd, Director General, GSMA. “Sp
Entersekt Sets Sights on the Nordics15.11.2018 11:00 | Tiedote
Entersekt, an innovator in mobile-first fintech solutions, today announced its entry into the competitive Nordic market. The identity and payments enablement provider serves banks and other enterprises operating in 45 countries. Entersekt’s interest in Scandinavia derives from its openness to digital banking and payments innovation. Digitization may be transforming business in every corner of the world, but few regions have experienced the wholesale change in consumer payments behaviour that the Nordics have. While governments, central banks, and the banking industry as a whole have pushed a cashless agenda for several years now, many point to Nordic consumers’ enthusiastic adoption of cashless transacting as the true driver behind the boom in digital payments. Consumers in the region have never been hidebound to payments innovation, as smart card penetration rates demonstrated years ago. Payments-ready smartphones are, of course, everywhere and the retail NFC infrastructure is superb.
Mobidiag nostaa viimeisen €4M erän Euroopan investointipankin €15M rahoituksesta15.11.2018 09:30 | Tiedote
Mobidiag Oy, vahvassa kasvuvaiheessa oleva molekyylidiagnostiikkayhtiö, joka taistelee antibioottiresistenssin leviämistä vastaan, ilmoitti tänään, että se on nostanut viimeisen 4 miljoonan euron erän 15 miljoonan euron lainasta, jonka Euroopan investointipankki (EIP) myönsi yhtiölle kolmivuotiseen projektiin heinäkuussa 2016. Laina myönnettiin osana EIP:n ”InnovFin - EU Finance for innovators” -ohjelmaa. Ohjelman tavoitteena on tukea innovatiivisten eurooppalaisten yhtiöiden haastavia korkean teknologian kehityshankkeita mahdollistamalla rahoituksen. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20181114005789/fi/ Aiemmin nostettujen EIP:n lainaerien avulla Mobidiag on kehittänyt valmiiksi ja kaupallistanut Novodiag® -molekyylidiagnostiikan järjestelmänsä sekä kaksi suolistoinfektioiden aiheuttajien tunnistamiseen käytettävää testiä (Novodiag® C. difficile ja Novodiag® Bacterial GE+). Viimeisen lainaerän avulla yhtiö nope
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme